Dipraglurant clinical trials
Also written ADX48621.
How each study uses dipraglurant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2021 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Addex Pharma S.A. (4) · Johns Hopkins University (1)
Studies
Open first, then newest update. How each study uses dipraglurant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With BlepharospasmCompletedPhase 2Addex Pharma S.A.NCT05027997Written as Dipraglurant
- Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based TherapyTerminatedPhase 2/3Addex Pharma S.A.NCT05116813Written as Dipraglurant
- Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based TherapyTerminatedPhase 2/3Addex Pharma S.A.NCT04857359Written as Dipraglurant
- PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) AdministrationCompletedPhase 1Johns Hopkins UniversityNCT02447640Written as ADX48621
- ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's DiseaseCompletedPhase 2Addex Pharma S.A.NCT01336088Written as ADX48621
Codes
What other systems call dipraglurant · ClinicalTrials.gg INT000189
- MeSH (NLM) C0005960956-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) CV8JZR21A1DIPRAGLURANTConfirmed FDA, NLM, Wikidata
- Wikidata Q19596938dipraglurantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171677DipraglurantOne source FDA
- DrugBank DB12733One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596095 | 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | CV8JZR21A1 | DIPRAGLURANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19596938 | dipraglurant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171677 | Dipraglurant | One source FDA |
| DrugBank | DB12733 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.